Karczmarek-Borowska Bozenna, Filip Agata, Wojcierowski Jacek, Smoleń Agata, Korobowicz Elzbieta, Korszen-Pilecka Iwona, Zdunek Małgorzata
The Oncology Center of Lublin Land, and Department of Human Genetics, Medical University of Lublin, Poland.
Lung Cancer. 2006 Jan;51(1):61-9. doi: 10.1016/j.lungcan.2005.08.010. Epub 2005 Nov 16.
The aim of our study was to estimate the expression of the Bcl-xL gene, a member of Bcl-2 family, in NSCLC patients. A total of 60 consecutive patients diagnosed with NSCLC that underwent chemotherapy prior to surgery were reviewed. Bcl-xL expression was assessed on paraffin sections by in situ hybridization (ISH) and immunohistochemistry (IMH). We observed the presence of mRNA of Bcl-xL gene and its protein product overexpression in most patients (60 and 81.7%, respectively). In material examined no significant correlation was observed between the pattern of Bcl-xL or protein expression and any clinicopathological factors evaluated. The expression of Bcl-xL protein was low (less than 10% positive cells) in 11 patients (median survival time 29 months) as compared to 49 patients with overexpression (median survival time 21.0 months). The difference was not of statistic significance (p=0.27). In examined group the Bcl-xL mRNA was found in 36 patients, while it was absent in 24 cases. Median survival time was 14.5 and 86.5 months, respectively (p=0.001). In addition, 19.4% of 5-year survivals were achieved in patients with overexpression and 54.2% in patients with no mRNA present (p=0.002). The percentage of 5-year survival in patients with protein expression assessed by IMH was 30.6% (p=0.31). The estimation of Bcl-xL expression on mRNA and protein level was compared by the means of sign test and the significant difference was found (p=0.009). The inconsistency was related to 35% of cases. In comparison with IMH, ISH technique appeared to be more specific and accurate in assessment of 5-year survival (25 and 65%; 65 and 70%, respectively). The results of our study indicate that Bcl-xL mRNA overexpression may suggest poor prognosis in NSCLC.
我们研究的目的是评估NSCLC患者中Bcl-2家族成员Bcl-xL基因的表达情况。回顾了60例连续诊断为NSCLC且在手术前接受化疗的患者。通过原位杂交（ISH）和免疫组织化学（IMH）在石蜡切片上评估Bcl-xL的表达。我们观察到大多数患者（分别为60%和81.7%）存在Bcl-xL基因的mRNA及其蛋白产物过表达。在所检查的材料中，未观察到Bcl-xL或蛋白表达模式与任何评估的临床病理因素之间存在显著相关性。11例患者（中位生存时间29个月）的Bcl-xL蛋白表达较低（阳性细胞少于10%），而49例过表达患者的中位生存时间为21.0个月。差异无统计学意义（p=0.27）。在检查组中，36例患者发现Bcl-xL mRNA，24例未发现。中位生存时间分别为14.5个月和86.5个月（p=0.001）。此外，过表达患者的5年生存率为19.4%，无mRNA患者为54.2%（p=0.002）。通过IMH评估蛋白表达的患者5年生存率为30.6%（p=0.31）。通过符号检验比较了Bcl-xL在mRNA和蛋白水平上的表达估计，发现存在显著差异（p=0.009）。不一致性与35%的病例有关。与IMH相比，ISH技术在评估5年生存率方面似乎更具特异性和准确性（分别为25%和65%；65%和70%）。我们的研究结果表明，Bcl-xL mRNA过表达可能提示NSCLC预后不良。
